AbbVie (MEX:ABBV) ROE % Adjusted to Book Value: Negative Equity% (As of Mar. 2026)


MEX:ABBV AbbVie Inc MEX:ABBV
72 GF Score
Price MXN4,343.00
GF Value MXN3,624.05
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie ROE % Adjusted to Book Value?

AbbVie MEX:ABBV +2.31% 72 ROE % Adjusted to Book Value is Negative Equity% as of Mar. 2026. GuruFocus rates MEX:ABBV with a GF Score™ of 72/100 and a GF Value™ of MXN3,624.05 (Modestly Overvalued). The stock has 4 warning signs investors should review.

AbbVie's ROE % for the quarter that ended in Mar. 2026 was Negative Equity. AbbVie's PB Ratio for the quarter that ended in Mar. 2026 was N/A. AbbVie's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was Negative Equity.

AbbVie ROE % Adjusted to Book Value Related Terms

AbbVie ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for AbbVie's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie ROE % Adjusted to Book Value Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.26 4.19 1.23 0.79 0.00

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.00 Negative Equity Negative Equity Negative Equity

MEX:ABBV vs MRK, JNJ, AMGN: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - General subindustry, AbbVie's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbbVie ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where AbbVie's ROE % Adjusted to Book Value falls into.


MEX:ABBV
72GF Score
AbbVie Inc MEX:ABBV
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie ROE % Adjusted to Book Value Calculation

AbbVie's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=1,454.00% / N/A
=N/A

AbbVie's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of Negative Equity% mean?
AbbVie (MEX:ABBV) has a ROE % Adjusted to Book Value of Negative Equity% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on AbbVie and its competitors.
Is AbbVie's ROE % Adjusted to Book Value too high?
AbbVie's current ROE % Adjusted to Book Value is Negative Equity%. Overall, AbbVie has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's ROE % Adjusted to Book Value compare to MRK and JNJ?
AbbVie's ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on AbbVie and its competitors. AbbVie's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (MEX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN3,624.05, compared to a current price of MXN4,343.00 — trading 19.8% above its estimated fair value. The current ROE % Adjusted to Book Value is Negative Equity%. AbbVie's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For AbbVie (MEX:ABBV), the current ROE % Adjusted to Book Value is Negative Equity% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (MEX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of MXN4,343.00 is trading 19.8% above its estimated GF Value™ of MXN3,624.05. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for MEX:ABBV:

  • ROE % Adjusted to Book Value: Negative Equity%
  • GF Value™: MXN3,624.05 vs. price of MXN4,343.00 (19.8% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
72GF Score

Get the complete analysis for MEX:ABBV

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,343.00
Price
MXN3,624.05
GF Value